Phase 2 N=22 Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer
Head and Neck Carcinoma
Primary: Overall Response Rate — 22.7 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=18 Evaluation of Tolerance, Suckling and Food Intake After Repeated Nasals Administrations of Oxytocin in PWS Infants
Prader Willi Syndrome
Primary: Occurence of Adverse Event — 10; 9; 6 number of adverse events
Phase 4 N=17 Immune Monitoring to Facilitate Belatacept Monotherapy
Kidney Transplant Rejection · Immunosuppression
Primary: Incidence of Acute Rejection — 0 Participants
Phase 2 N=22 Efficacy of SJ733 in Adults With Uncomplicated Plasmodium Falciparum or Vivax Malaria
Malaria, Falciparum · Malaria, Vivax
Primary: Crude Adequate Clinical and Parasitological Response (ACPR) — 90; 100 percentage of participants
N/A N=30 Active You: A Novel Exercise Program for African Americans
Cardiovascular Risk Factor · Prediabetes · Overweight and Obesity
Primary: Percentage of Participants Retained at the End of Study — 93.33; 93.33 Percent of enrolled participants
Phase 1 N=12 A Study to Evaluate RMC-035 in Subjects Undergoing Cardiac Surgery
Acute Kidney Injury (AKI)
Primary: Frequency of Adverse Events (AEs) — 6; 1; 3; 1 Participants
N/A N=124 Apogee, A HeartWare HVAD Destination Product Surveillance Registry (PSR) Platform
Chronic Heart Failure
Primary: Rate of Major Adverse Events — 18.2 % probability of freedom from major AE
N/A N=18 Web-Based Simulation Tool For Self-Management Support In Type 1 Diabetes Mellitus
Type 1 Diabetes
Primary: Technology Expectation and Technology Acceptance Questionnaires: Perceived Burdens and Benefits at Baseline and Week 5 (Post-intervention) — 25.0; 42.5; 58.9; 55.4…
Phase 2 N=183 A Study to Evaluate the Long-Term Safety and Efficacy of Bimekizumab in Subjects With Psoriatic Arthritis
Psoriatic Arthritis
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Study — 80.9 percentage of participants
Phase 3 N=380 Effect of Diacerein vs Celecoxib on Symptoms and Structural Changes in Symptomatic Knee Osteoarthritis
Osteoarthritis · Osteoarthritis, Knee
Primary: Change Form Baseline in WOMAC A Pain Subscale — -11.14; -11.82 cm — p=<0.025
Phase 2 N=124 Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension
Tourette Syndrome in Children · Tourette Syndrome in Adolescence
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) and Their Relationship (Unrelated, Possibly Related, or Probably Related) — 84; 2; 44…
Phase 1 N=12 Impact of Steady State Cobicistat and Darunavir/Cobicistat on the Pharmacokinetics and Pharmacodynamics of Oral Anticoagulants (Rivaroxaban, Apixaban) in Health Volunteers
Healthy Volunteers
Primary: Area Under the Concentration Versus Time Curve (AUC0-∞) for Rivaroxaban — 1049.19; 2274.3; 2226.38 hr*ng/ml
Phase 2 N=100 Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)
Gastric Cancer
Primary: Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)…
N/A N=115 PicoWay™ 730 Resolve Fusion for Benign Pigmented Lesions and Wrinkles
Benign Pigmented Lesions · Facial Wrinkles
Primary: Change in Wrinkles From Baseline to 12 Weeks Post-study Treatment Assessed by Blinded Photographic Evaluation Using 9-Point Fitzpatrick Wrinkle Scale
N/A N=140 Dural Puncture Epidural Versus Epidural Anesthesia for Cesarean Delivery
Pain Levels
Primary: Onset Time of Surgical Anesthesia — 422; 655 seconds